Search Results: Treatment + Breast Cancer (21 results)
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372/using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Treatment
Post-treatment study to monitor for recurrence
This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:
- Detect cancer recurrence early
- Predict outcomes after treatment
- Support future use of blood‑based monitoring instead of—or in addition to—imaging tests
For Adults With Advanced HR+ HER2- Breast Cancer, Not Yet Treated: Join the FourLight-3 Study
https://www.facingourrisk.org/research-clinical-trials/study/366/this-study-is-for-adults-with-advanced-hr-positive-her2-negative-breast-cancer-who-have-not-yet-received-treatment-for-their-advanced-disease
Treatment
Phase 3 study for adults with advanced HR-positive, HER2-negative breast cancer who have not yet received treatment for their advanced disease
The FourLight-3 clinical trial tests a study treatment, atrimociclib, plus letrozole against standard approved treatments plus letrozole. The clinical trial is for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who have not received prior treatment for advanced disease.
Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T
https://www.facingourrisk.org/research-clinical-trials/study/364/treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t
Treatment
Phase 1 treatment study for people with advanced solid tumors
CAR-T therapy is a type of immunotherapy that uses the patient's own immune cells in order to treat their cancer. With CAR-T therapy, the immune cells are removed from the blood and enhanced in the lab to improve their ability to kill cancer cells. The goal of this clinical trial is to learn the safety and effectiveness of an experimental CAR-T combination known as CLBR001+ABBV-461 for treating people with metastatic breast cancer. Another goal is to learn the best dose of this combination for treating metastatic breast cancer.
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363/testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359/study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat metastatic, triple-negative breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349/studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer.
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Treatment
Biomarker study for people with early-stage breast cancer
This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343/a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Treatment
Treatment study for early-stage triple-negative breast cancer
This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333/study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer
354 results
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT ID: NCT07318805 (https://clinicaltrials.gov/study/NCT07318805)
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
NCT ID: NCT05507879 (https://clinicaltrials.gov/study/NCT05507879)
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
NCT ID: NCT06953882 (https://clinicaltrials.gov/study/NCT06953882)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://clinicaltrials.gov/study/NCT06127979)
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://clinicaltrials.gov/study/NCT04427293)
Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision
NCT ID: NCT06572410 (https://clinicaltrials.gov/study/NCT06572410)
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT ID: NCT07115043 (https://clinicaltrials.gov/study/NCT07115043)
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT ID: NCT01000883 (https://clinicaltrials.gov/study/NCT01000883)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://clinicaltrials.gov/study/NCT04494945)
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://clinicaltrials.gov/study/NCT04824027)
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT ID: NCT06681233 (https://clinicaltrials.gov/study/NCT06681233)
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT ID: NCT03513614 (https://clinicaltrials.gov/study/NCT03513614)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://clinicaltrials.gov/study/NCT04360330)
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT ID: NCT05592938 (https://clinicaltrials.gov/study/NCT05592938)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT ID: NCT06966700 (https://clinicaltrials.gov/study/NCT06966700)
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT ID: NCT04888975 (https://clinicaltrials.gov/study/NCT04888975)
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT ID: NCT06678269 (https://clinicaltrials.gov/study/NCT06678269)
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NCT ID: NCT06055881 (https://clinicaltrials.gov/study/NCT06055881)
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
NCT ID: NCT05406232 (https://clinicaltrials.gov/study/NCT05406232)
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://clinicaltrials.gov/study/NCT04606030)
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://clinicaltrials.gov/study/NCT02926729)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT ID: NCT06247995 (https://clinicaltrials.gov/study/NCT06247995)
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
NCT ID: NCT06813053 (https://clinicaltrials.gov/study/NCT06813053)
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT ID: NCT07158021 (https://clinicaltrials.gov/study/NCT07158021)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://clinicaltrials.gov/study/NCT06006806)
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
NCT ID: NCT06260033 (https://clinicaltrials.gov/study/NCT06260033)
Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://clinicaltrials.gov/study/NCT04475640)
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT ID: NCT00353483 (https://clinicaltrials.gov/study/NCT00353483)
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
NCT ID: NCT05755269 (https://clinicaltrials.gov/study/NCT05755269)
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT ID: NCT04169542 (https://clinicaltrials.gov/study/NCT04169542)
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT ID: NCT04721886 (https://clinicaltrials.gov/study/NCT04721886)
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://clinicaltrials.gov/study/NCT05130801)
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT ID: NCT05964504 (https://clinicaltrials.gov/study/NCT05964504)
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT ID: NCT05315700 (https://clinicaltrials.gov/study/NCT05315700)
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
NCT ID: NCT06617455 (https://clinicaltrials.gov/study/NCT06617455)
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT ID: NCT06902311 (https://clinicaltrials.gov/study/NCT06902311)
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT ID: NCT06195306 (https://clinicaltrials.gov/study/NCT06195306)
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
NCT ID: NCT06445738 (https://clinicaltrials.gov/study/NCT06445738)
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT ID: NCT03936478 (https://clinicaltrials.gov/study/NCT03936478)
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT ID: NCT06252662 (https://clinicaltrials.gov/study/NCT06252662)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://clinicaltrials.gov/study/NCT04144023)
Factors Associated With Breast Cancer Risks and Outcomes
NCT ID: NCT07294703 (https://clinicaltrials.gov/study/NCT07294703)
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
NCT ID: NCT00823654 (https://clinicaltrials.gov/study/NCT00823654)
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT ID: NCT06673329 (https://clinicaltrials.gov/study/NCT06673329)
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://clinicaltrials.gov/study/NCT04521764)
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
NCT ID: NCT04985032 (https://clinicaltrials.gov/study/NCT04985032)
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06434064 (https://clinicaltrials.gov/study/NCT06434064)
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT ID: NCT04703244 (https://clinicaltrials.gov/study/NCT04703244)
A Registry Study of Breast Microseed Treatment
NCT ID: NCT02701244 (https://clinicaltrials.gov/study/NCT02701244)
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT ID: NCT04038619 (https://clinicaltrials.gov/study/NCT04038619)
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT ID: NCT06113016 (https://clinicaltrials.gov/study/NCT06113016)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT ID: NCT07020117 (https://clinicaltrials.gov/study/NCT07020117)
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT ID: NCT06538389 (https://clinicaltrials.gov/study/NCT06538389)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://clinicaltrials.gov/study/NCT03488693)
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT ID: NCT07211178 (https://clinicaltrials.gov/study/NCT07211178)
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT ID: NCT06582615 (https://clinicaltrials.gov/study/NCT06582615)
Active Surveillance in Older Women With ER+ Breast Cancer
NCT ID: NCT07262138 (https://clinicaltrials.gov/study/NCT07262138)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://clinicaltrials.gov/study/NCT06058377)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)
Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT ID: NCT06998407 (https://clinicaltrials.gov/study/NCT06998407)
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
NCT ID: NCT05417867 (https://clinicaltrials.gov/study/NCT05417867)
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT ID: NCT05472792 (https://clinicaltrials.gov/study/NCT05472792)
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
NCT ID: NCT04766190 (https://clinicaltrials.gov/study/NCT04766190)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT ID: NCT04871139 (https://clinicaltrials.gov/study/NCT04871139)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT ID: NCT05705401 (https://clinicaltrials.gov/study/NCT05705401)
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
NCT ID: NCT06999798 (https://clinicaltrials.gov/study/NCT06999798)
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT ID: NCT06144164 (https://clinicaltrials.gov/study/NCT06144164)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://clinicaltrials.gov/study/NCT05378464)
Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT ID: NCT05595577 (https://clinicaltrials.gov/study/NCT05595577)
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer
NCT ID: NCT06671730 (https://clinicaltrials.gov/study/NCT06671730)
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
NCT ID: NCT06966388 (https://clinicaltrials.gov/study/NCT06966388)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT ID: NCT06797635 (https://clinicaltrials.gov/study/NCT06797635)
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://clinicaltrials.gov/study/NCT05464082)
Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://clinicaltrials.gov/study/NCT05020574)
Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
NCT ID: NCT07137468 (https://clinicaltrials.gov/study/NCT07137468)
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT ID: NCT06058650 (https://clinicaltrials.gov/study/NCT06058650)
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT ID: NCT06995898 (https://clinicaltrials.gov/study/NCT06995898)
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06910761 (https://clinicaltrials.gov/study/NCT06910761)
Acute Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer Patients With the Use of Silver-Plated Technology
NCT ID: NCT06831084 (https://clinicaltrials.gov/study/NCT06831084)
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
NCT ID: NCT05056857 (https://clinicaltrials.gov/study/NCT05056857)
A Study of Surgery and Radiotherapy in People With Breast Cancer
NCT ID: NCT07053085 (https://clinicaltrials.gov/study/NCT07053085)
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
NCT ID: NCT07066189 (https://clinicaltrials.gov/study/NCT07066189)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://clinicaltrials.gov/study/NCT05412225)
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
NCT ID: NCT05134779 (https://clinicaltrials.gov/study/NCT05134779)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://clinicaltrials.gov/study/NCT04553770)
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
NCT ID: NCT06574022 (https://clinicaltrials.gov/study/NCT06574022)
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT ID: NCT04638751 (https://clinicaltrials.gov/study/NCT04638751)
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
NCT ID: NCT07087691 (https://clinicaltrials.gov/study/NCT07087691)
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT ID: NCT07064018 (https://clinicaltrials.gov/study/NCT07064018)
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
NCT ID: NCT07308717 (https://clinicaltrials.gov/study/NCT07308717)
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
NCT ID: NCT05590949 (https://clinicaltrials.gov/study/NCT05590949)
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT ID: NCT05941520 (https://clinicaltrials.gov/study/NCT05941520)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
NCT ID: NCT06450873 (https://clinicaltrials.gov/study/NCT06450873)
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT ID: NCT06896162 (https://clinicaltrials.gov/study/NCT06896162)
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT06954831 (https://clinicaltrials.gov/study/NCT06954831)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://clinicaltrials.gov/study/NCT04588545)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
NCT ID: NCT07214610 (https://clinicaltrials.gov/study/NCT07214610)
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NCT ID: NCT06103669 (https://clinicaltrials.gov/study/NCT06103669)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT ID: NCT06876714 (https://clinicaltrials.gov/study/NCT06876714)
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
NCT ID: NCT07076485 (https://clinicaltrials.gov/study/NCT07076485)
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT ID: NCT06224673 (https://clinicaltrials.gov/study/NCT06224673)
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT ID: NCT05463796 (https://clinicaltrials.gov/study/NCT05463796)
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
NCT ID: NCT06860815 (https://clinicaltrials.gov/study/NCT06860815)
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://clinicaltrials.gov/study/NCT02977468)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://clinicaltrials.gov/study/NCT04563507)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NCT ID: NCT07224464 (https://clinicaltrials.gov/study/NCT07224464)
Two Versus One Week Breast Radiotherapy (RT)
NCT ID: NCT06960707 (https://clinicaltrials.gov/study/NCT06960707)
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://clinicaltrials.gov/study/NCT05766891)
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT ID: NCT04799535 (https://clinicaltrials.gov/study/NCT04799535)
IKS014 in Advanced Solid Tumors That Express HER2
NCT ID: NCT05872295 (https://clinicaltrials.gov/study/NCT05872295)
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT ID: NCT06731894 (https://clinicaltrials.gov/study/NCT06731894)
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT ID: NCT04022616 (https://clinicaltrials.gov/study/NCT04022616)
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://clinicaltrials.gov/study/NCT05505643)
Oral Aromatase Inhibitors Modify the Gut Microbiome
NCT ID: NCT05030038 (https://clinicaltrials.gov/study/NCT05030038)
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://clinicaltrials.gov/study/NCT04711824)
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://clinicaltrials.gov/study/NCT05528133)
The PREDICT Registry:
NCT ID: NCT03448926 (https://clinicaltrials.gov/study/NCT03448926)
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://clinicaltrials.gov/study/NCT04852887)
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
NCT ID: NCT02772367 (https://clinicaltrials.gov/study/NCT02772367)
A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
NCT ID: NCT06772181 (https://clinicaltrials.gov/study/NCT06772181)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Study of DF1001 in Patients with Advanced Solid Tumors
NCT ID: NCT04143711 (https://clinicaltrials.gov/study/NCT04143711)
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://clinicaltrials.gov/study/NCT04084730)
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT ID: NCT07220967 (https://clinicaltrials.gov/study/NCT07220967)
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://clinicaltrials.gov/study/NCT04389281)
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://clinicaltrials.gov/study/NCT03694756)
Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery
NCT ID: NCT06524895 (https://clinicaltrials.gov/study/NCT06524895)
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT ID: NCT05890677 (https://clinicaltrials.gov/study/NCT05890677)
NearWave Optical Molecular Monitoring
NCT ID: NCT06744465 (https://clinicaltrials.gov/study/NCT06744465)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT ID: NCT04650256 (https://clinicaltrials.gov/study/NCT04650256)
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://clinicaltrials.gov/study/NCT05856773)
Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://clinicaltrials.gov/study/NCT04074720)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://clinicaltrials.gov/study/NCT04967976)
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT05736367 (https://clinicaltrials.gov/study/NCT05736367)
Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://clinicaltrials.gov/study/NCT05464667)
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT ID: NCT06327490 (https://clinicaltrials.gov/study/NCT06327490)
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT ID: NCT06184750 (https://clinicaltrials.gov/study/NCT06184750)
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT ID: NCT06347068 (https://clinicaltrials.gov/study/NCT06347068)
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT07112053 (https://clinicaltrials.gov/study/NCT07112053)
Biomarkers to Detect Endocrine Therapy Resistance
NCT ID: NCT06067503 (https://clinicaltrials.gov/study/NCT06067503)
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
NCT ID: NCT07206121 (https://clinicaltrials.gov/study/NCT07206121)
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT ID: NCT06993844 (https://clinicaltrials.gov/study/NCT06993844)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
NCT ID: NCT06763328 (https://clinicaltrials.gov/study/NCT06763328)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://clinicaltrials.gov/study/NCT05677802)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04368702 (https://clinicaltrials.gov/study/NCT04368702)
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT ID: NCT03524430 (https://clinicaltrials.gov/study/NCT03524430)
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
NCT ID: NCT06444269 (https://clinicaltrials.gov/study/NCT06444269)
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT ID: NCT06318897 (https://clinicaltrials.gov/study/NCT06318897)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://clinicaltrials.gov/study/NCT04234386)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT ID: NCT06926868 (https://clinicaltrials.gov/study/NCT06926868)
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
NCT ID: NCT07242118 (https://clinicaltrials.gov/study/NCT07242118)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
NCT ID: NCT06461650 (https://clinicaltrials.gov/study/NCT06461650)
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://clinicaltrials.gov/study/NCT04998682)
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients
NCT ID: NCT05585788 (https://clinicaltrials.gov/study/NCT05585788)
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT ID: NCT05633654 (https://clinicaltrials.gov/study/NCT05633654)
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
NCT ID: NCT03255577 (https://clinicaltrials.gov/study/NCT03255577)
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
NCT ID: NCT00898131 (https://clinicaltrials.gov/study/NCT00898131)
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
NCT ID: NCT06897488 (https://clinicaltrials.gov/study/NCT06897488)
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://clinicaltrials.gov/study/NCT05704283)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)
SAVE Trial: SAfe Opioid Use Video Education
NCT ID: NCT07044583 (https://clinicaltrials.gov/study/NCT07044583)
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT ID: NCT04969835 (https://clinicaltrials.gov/study/NCT04969835)
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
NCT ID: NCT06300411 (https://clinicaltrials.gov/study/NCT06300411)
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT ID: NCT06238921 (https://clinicaltrials.gov/study/NCT06238921)
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT ID: NCT05037825 (https://clinicaltrials.gov/study/NCT05037825)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://clinicaltrials.gov/study/NCT04683679)
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
NCT ID: NCT01788839 (https://clinicaltrials.gov/study/NCT01788839)
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
NCT ID: NCT07209436 (https://clinicaltrials.gov/study/NCT07209436)
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT05081609 (https://clinicaltrials.gov/study/NCT05081609)
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06637306 (https://clinicaltrials.gov/study/NCT06637306)
BREAST Choice Decision Tool R21 - AIM2
NCT ID: NCT06817226 (https://clinicaltrials.gov/study/NCT06817226)
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://clinicaltrials.gov/study/NCT04990921)
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
NCT ID: NCT06700070 (https://clinicaltrials.gov/study/NCT06700070)
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT ID: NCT07016399 (https://clinicaltrials.gov/study/NCT07016399)
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT ID: NCT06172127 (https://clinicaltrials.gov/study/NCT06172127)
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery
NCT ID: NCT07335354 (https://clinicaltrials.gov/study/NCT07335354)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
A Study of Blood Pressure Control During Cancer Treatment
NCT ID: NCT06023576 (https://clinicaltrials.gov/study/NCT06023576)
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
NCT ID: NCT03987555 (https://clinicaltrials.gov/study/NCT03987555)
Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study
NCT ID: NCT05703399 (https://clinicaltrials.gov/study/NCT05703399)
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
NCT ID: NCT06961955 (https://clinicaltrials.gov/study/NCT06961955)
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://clinicaltrials.gov/study/NCT05703269)
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT ID: NCT06952803 (https://clinicaltrials.gov/study/NCT06952803)
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://clinicaltrials.gov/study/NCT06153836)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://clinicaltrials.gov/study/NCT04677816)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://clinicaltrials.gov/study/NCT05812807)
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT ID: NCT06833502 (https://clinicaltrials.gov/study/NCT06833502)
Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications
NCT ID: NCT05046301 (https://clinicaltrials.gov/study/NCT05046301)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT ID: NCT06841354 (https://clinicaltrials.gov/study/NCT06841354)
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT ID: NCT06888388 (https://clinicaltrials.gov/study/NCT06888388)
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT ID: NCT06727773 (https://clinicaltrials.gov/study/NCT06727773)
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
NCT ID: NCT05561842 (https://clinicaltrials.gov/study/NCT05561842)
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://clinicaltrials.gov/study/NCT05607004)
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT ID: NCT04373564 (https://clinicaltrials.gov/study/NCT04373564)
National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://clinicaltrials.gov/study/NCT05534438)
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://clinicaltrials.gov/study/NCT04003038)
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT ID: NCT03546686 (https://clinicaltrials.gov/study/NCT03546686)
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT ID: NCT06507618 (https://clinicaltrials.gov/study/NCT06507618)
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
NCT ID: NCT06903468 (https://clinicaltrials.gov/study/NCT06903468)
The Immune System's Response to Young Women's Breast Cancer
NCT ID: NCT01503190 (https://clinicaltrials.gov/study/NCT01503190)
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
NCT ID: NCT05972343 (https://clinicaltrials.gov/study/NCT05972343)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://clinicaltrials.gov/study/NCT03796559)
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women
NCT ID: NCT06635005 (https://clinicaltrials.gov/study/NCT06635005)
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
NCT ID: NCT07014618 (https://clinicaltrials.gov/study/NCT07014618)
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT ID: NCT03643861 (https://clinicaltrials.gov/study/NCT03643861)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT ID: NCT06393374 (https://clinicaltrials.gov/study/NCT06393374)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://clinicaltrials.gov/study/NCT03604315)
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
NCT ID: NCT06904365 (https://clinicaltrials.gov/study/NCT06904365)
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
NCT ID: NCT07044310 (https://clinicaltrials.gov/study/NCT07044310)
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
NCT ID: NCT06981208 (https://clinicaltrials.gov/study/NCT06981208)
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT ID: NCT06512350 (https://clinicaltrials.gov/study/NCT06512350)
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://clinicaltrials.gov/study/NCT06185205)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://clinicaltrials.gov/study/NCT05218044)
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834 (https://clinicaltrials.gov/study/NCT02290834)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT07085767 (https://clinicaltrials.gov/study/NCT07085767)
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT ID: NCT06780176 (https://clinicaltrials.gov/study/NCT06780176)
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://clinicaltrials.gov/study/NCT04371913)
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT06878248 (https://clinicaltrials.gov/study/NCT06878248)
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://clinicaltrials.gov/study/NCT04454528)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)
Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes
NCT ID: NCT06078761 (https://clinicaltrials.gov/study/NCT06078761)
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT ID: NCT07017673 (https://clinicaltrials.gov/study/NCT07017673)
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
NCT ID: NCT07327489 (https://clinicaltrials.gov/study/NCT07327489)
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://clinicaltrials.gov/study/NCT05269160)
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
NCT ID: NCT07166042 (https://clinicaltrials.gov/study/NCT07166042)
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT ID: NCT03463954 (https://clinicaltrials.gov/study/NCT03463954)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)
CDK and Body Composition Study
NCT ID: NCT03697577 (https://clinicaltrials.gov/study/NCT03697577)
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
NCT ID: NCT06315296 (https://clinicaltrials.gov/study/NCT06315296)
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT ID: NCT06500481 (https://clinicaltrials.gov/study/NCT06500481)
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT ID: NCT06590857 (https://clinicaltrials.gov/study/NCT06590857)
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT ID: NCT06502691 (https://clinicaltrials.gov/study/NCT06502691)
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://clinicaltrials.gov/study/NCT05351424)
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://clinicaltrials.gov/study/NCT05190978)
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://clinicaltrials.gov/study/NCT01766297)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)
A Study of the TheraBionic P1 Device in Breast Cancer
NCT ID: NCT07218432 (https://clinicaltrials.gov/study/NCT07218432)
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://clinicaltrials.gov/study/NCT05325632)
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05741164 (https://clinicaltrials.gov/study/NCT05741164)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://clinicaltrials.gov/study/NCT05313191)
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT ID: NCT03096418 (https://clinicaltrials.gov/study/NCT03096418)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://clinicaltrials.gov/study/NCT04899908)
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT ID: NCT02000089 (https://clinicaltrials.gov/study/NCT02000089)
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
NCT ID: NCT03536897 (https://clinicaltrials.gov/study/NCT03536897)
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://clinicaltrials.gov/study/NCT06220214)
EMBRACE: Exercising Together
NCT ID: NCT06049355 (https://clinicaltrials.gov/study/NCT06049355)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://clinicaltrials.gov/study/NCT03572374)
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT ID: NCT06253871 (https://clinicaltrials.gov/study/NCT06253871)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT ID: NCT07285044 (https://clinicaltrials.gov/study/NCT07285044)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://clinicaltrials.gov/study/NCT05291507)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT ID: NCT06500455 (https://clinicaltrials.gov/study/NCT06500455)
Core Biopsies for Establishing a Breast Tumor Tissue Repository
NCT ID: NCT02250352 (https://clinicaltrials.gov/study/NCT02250352)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Intra-Operative Radiation Registry
NCT ID: NCT04994067 (https://clinicaltrials.gov/study/NCT04994067)
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
NCT ID: NCT07137416 (https://clinicaltrials.gov/study/NCT07137416)
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
NCT ID: NCT05996107 (https://clinicaltrials.gov/study/NCT05996107)
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
NCT ID: NCT04603209 (https://clinicaltrials.gov/study/NCT04603209)
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://clinicaltrials.gov/study/NCT06139107)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://clinicaltrials.gov/study/NCT03808337)
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://clinicaltrials.gov/study/NCT06295744)
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT ID: NCT06388122 (https://clinicaltrials.gov/study/NCT06388122)
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
NCT ID: NCT06525766 (https://clinicaltrials.gov/study/NCT06525766)
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT ID: NCT06324240 (https://clinicaltrials.gov/study/NCT06324240)
GammaPod Registry and Quality of Life Nomogram
NCT ID: NCT03562273 (https://clinicaltrials.gov/study/NCT03562273)
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
NCT ID: NCT07231159 (https://clinicaltrials.gov/study/NCT07231159)
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://clinicaltrials.gov/study/NCT01042379)
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT ID: NCT06856499 (https://clinicaltrials.gov/study/NCT06856499)
WashU DIEP Flap Video and Patient Understanding Improvement
NCT ID: NCT06864754 (https://clinicaltrials.gov/study/NCT06864754)
Dance Study for Post-surgical Pain in Breast Cancer Survivors
NCT ID: NCT06758102 (https://clinicaltrials.gov/study/NCT06758102)
Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
NCT ID: NCT06953245 (https://clinicaltrials.gov/study/NCT06953245)
Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery
NCT ID: NCT06297265 (https://clinicaltrials.gov/study/NCT06297265)
Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://clinicaltrials.gov/study/NCT06165419)
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://clinicaltrials.gov/study/NCT05219695)
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://clinicaltrials.gov/study/NCT05595499)
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06518057 (https://clinicaltrials.gov/study/NCT06518057)
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT ID: NCT05064098 (https://clinicaltrials.gov/study/NCT05064098)
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://clinicaltrials.gov/study/NCT01185132)
Intravital Microscopy in Human Solid Tumors
NCT ID: NCT03823144 (https://clinicaltrials.gov/study/NCT03823144)
Breast Cancer Survivorship Biorepository
NCT ID: NCT05786664 (https://clinicaltrials.gov/study/NCT05786664)
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT ID: NCT03941756 (https://clinicaltrials.gov/study/NCT03941756)
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)
Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://clinicaltrials.gov/study/NCT04636710)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://clinicaltrials.gov/study/NCT05894239)
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
NCT ID: NCT07095114 (https://clinicaltrials.gov/study/NCT07095114)
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://clinicaltrials.gov/study/NCT06129747)
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://clinicaltrials.gov/study/NCT05637216)
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
NCT ID: NCT06428682 (https://clinicaltrials.gov/study/NCT06428682)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT ID: NCT07140172 (https://clinicaltrials.gov/study/NCT07140172)
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://clinicaltrials.gov/study/NCT05892068)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://clinicaltrials.gov/study/NCT05146297)
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
NCT ID: NCT06294574 (https://clinicaltrials.gov/study/NCT06294574)
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT ID: NCT07118176 (https://clinicaltrials.gov/study/NCT07118176)
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://clinicaltrials.gov/study/NCT05774678)
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
NCT ID: NCT04517838 (https://clinicaltrials.gov/study/NCT04517838)
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
NCT ID: NCT05746325 (https://clinicaltrials.gov/study/NCT05746325)
Lymphedema Surveillance Study
NCT ID: NCT02743858 (https://clinicaltrials.gov/study/NCT02743858)
Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://clinicaltrials.gov/study/NCT06086704)
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://clinicaltrials.gov/study/NCT03351348)
Breast Re-irradiation After Second Ipsilateral Lumpectomy
NCT ID: NCT06867484 (https://clinicaltrials.gov/study/NCT06867484)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://clinicaltrials.gov/study/NCT05183828)
Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://clinicaltrials.gov/study/NCT04049214)
Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
NCT ID: NCT04715958 (https://clinicaltrials.gov/study/NCT04715958)
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT ID: NCT04567420 (https://clinicaltrials.gov/study/NCT04567420)
Definitive Radiation Therapy for Inoperable Breast Cancer
NCT ID: NCT07122713 (https://clinicaltrials.gov/study/NCT07122713)
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT ID: NCT06635980 (https://clinicaltrials.gov/study/NCT06635980)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT ID: NCT06686394 (https://clinicaltrials.gov/study/NCT06686394)
ERAS Protocols in Breast Conserving Surgery
NCT ID: NCT06938581 (https://clinicaltrials.gov/study/NCT06938581)
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://clinicaltrials.gov/study/NCT05245812)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT ID: NCT06435351 (https://clinicaltrials.gov/study/NCT06435351)
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://clinicaltrials.gov/study/NCT05557877)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.